Cancer Clinical Trial - OncoResponse-OR2805-101

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor

Drug

OR2805, Pembrolizumab, Nivolumab

Phase

Phase I

Condition

Advanced Solid Tumors Melanoma Sarcoma

Keywords

CD163